Screener
Castle Biosciences CSTL Total Current Liabilities
Total Current Liabilities at other companies
Other financials
Where this comes from
Reported directly by Castle Biosciences in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesCurrent.
The source filing: Castle Biosciences’s 10-Q, filed May 6, 2026.
- Filed
- May 6, 2026, 4:09 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-031263
| ASSETS | March 31, 2026 / (unaudited) | December 31, 2025 |
|---|---|---|
| Operating lease liabilities | 1,254 | 1,325 |
| Current portion of long-term debt | 1,667 | 417 |
| Other accrued and current liabilities | 10,691 | 8,937 |
| Total current liabilities | 48,761 | 68,677 |
| Long-term debt | 8,399 | 9,640 |
| Noncurrent portion of contingent consideration | 1,500 | 1,500 |
| Noncurrent operating lease liabilities | 25,116 | 25,217 |
| Noncurrent finance lease liabilities | 288 | 314 |
Item 1. Financial Statements.
FAQ
- What is Castle Biosciences's total current liabilities?
- Castle Biosciences (CSTL) reported total current liabilities of $48.76M in Q1 2026.
- How has Castle Biosciences's total current liabilities changed year-over-year?
- Castle Biosciences's total current liabilities increased by 30.8% year-over-year, from $37.27M to $48.76M.
- What is the long-term trend for Castle Biosciences's total current liabilities?
- Over 5 years (2020 to 2025), Castle Biosciences's total current liabilities has grown at a 26.9% compound annual growth rate (CAGR), from $20.88M to $68.68M.
- What does total current liabilities mean?
- The sum of all obligations due within one year — payables, accrued expenses, current debt, deferred revenue, and other short-term liabilities.
Ask your AI about Castle Biosciences's total current liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude